Brasada Capital Management LP Acquires 20,138 Shares of Solventum Corporation $SOLV

Brasada Capital Management LP grew its holdings in Solventum Corporation (NYSE:SOLV) by 32.4% in the 4th quarter, Holdings Channel reports. The fund owned 82,383 shares of the company’s stock after purchasing an additional 20,138 shares during the quarter. Solventum comprises 1.1% of Brasada Capital Management LP’s portfolio, making the stock its 28th biggest holding. Brasada Capital Management LP’s holdings in Solventum were worth $6,510,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of SOLV. Independent Franchise Partners LLP boosted its position in shares of Solventum by 27.2% in the third quarter. Independent Franchise Partners LLP now owns 12,899,240 shares of the company’s stock valued at $941,645,000 after acquiring an additional 2,758,174 shares during the period. Norges Bank bought a new stake in shares of Solventum in the fourth quarter valued at approximately $147,467,000. Diamond Hill Capital Management Inc. boosted its position in shares of Solventum by 152.2% in the fourth quarter. Diamond Hill Capital Management Inc. now owns 2,109,027 shares of the company’s stock valued at $167,119,000 after acquiring an additional 1,272,921 shares during the period. Boston Partners boosted its position in shares of Solventum by 26.1% in the third quarter. Boston Partners now owns 4,630,300 shares of the company’s stock valued at $338,006,000 after acquiring an additional 959,543 shares during the period. Finally, Vanguard Group Inc. boosted its position in shares of Solventum by 5.3% in the third quarter. Vanguard Group Inc. now owns 17,121,198 shares of the company’s stock valued at $1,249,847,000 after acquiring an additional 867,837 shares during the period.

Solventum Stock Down 0.5%

Shares of SOLV stock opened at $78.85 on Friday. The stock has a market cap of $13.66 billion, a P/E ratio of 9.66, a price-to-earnings-growth ratio of 1.22 and a beta of 0.69. Solventum Corporation has a one year low of $62.38 and a one year high of $88.20. The stock has a fifty day moving average price of $72.50 and a 200 day moving average price of $75.26. The company has a debt-to-equity ratio of 0.96, a current ratio of 1.07 and a quick ratio of 0.75.

Solventum (NYSE:SOLV) last issued its earnings results on Tuesday, May 5th. The company reported $1.48 EPS for the quarter, topping the consensus estimate of $1.35 by $0.13. The firm had revenue of $2.01 billion during the quarter, compared to analysts’ expectations of $1.97 billion. Solventum had a return on equity of 23.51% and a net margin of 17.33%.Solventum’s quarterly revenue was down 3.0% compared to the same quarter last year. During the same period last year, the business earned $1.34 earnings per share. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. Analysts predict that Solventum Corporation will post 6.58 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have recently weighed in on SOLV. KeyCorp increased their price objective on Solventum from $92.00 to $93.00 and gave the company an “overweight” rating in a research report on Wednesday, May 6th. Piper Sandler reduced their target price on Solventum from $98.00 to $92.00 and set an “overweight” rating for the company in a research report on Friday, April 17th. Weiss Ratings raised Solventum from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday. Wells Fargo & Company reduced their target price on Solventum from $83.00 to $70.00 and set an “equal weight” rating for the company in a research report on Wednesday, May 6th. Finally, UBS Group cut Solventum from a “buy” rating to a “neutral” rating and set a $50.00 target price for the company. in a research report on Thursday, May 14th. Eight equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $84.25.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.